The 36-month beta value for VIRI is also noteworthy at 1.85. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for VIRI is 14.86M, and at present, short sellers hold a 1.44% of that float. The average trading volume of VIRI on May 10, 2024 was 293.98K shares.
VIRI) stock’s latest price update
The stock price of Virios Therapeutics Inc (NASDAQ: VIRI) has dropped by -13.15 compared to previous close of 0.43. Despite this, the company has seen a fall of -11.54% in its stock price over the last five trading days. GlobeNewsWire reported 2024-05-02 that ATLANTA, May 02, 2024 (GLOBE NEWSWIRE) — Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), announced today that it will report first quarter 2024 financial results on Thursday, May 9, 2024 before the open of the financial markets. Management will also host a webcast and conference call on May 9, 2024 at 8:30 a.m. ET to discuss the results and provide a corporate update.
VIRI’s Market Performance
VIRI’s stock has fallen by -11.54% in the past week, with a monthly drop of -19.87% and a quarterly drop of -7.77%. The volatility ratio for the week is 10.16% while the volatility levels for the last 30 days are 9.75% for Virios Therapeutics Inc The simple moving average for the last 20 days is -16.32% for VIRI’s stock, with a simple moving average of -47.80% for the last 200 days.
VIRI Trading at -11.34% from the 50-Day Moving Average
After a stumble in the market that brought VIRI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -84.60% of loss for the given period.
Volatility was left at 9.75%, however, over the last 30 days, the volatility rate increased by 10.16%, as shares sank -22.36% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -1.92% lower at present.
During the last 5 trading sessions, VIRI fell by -11.54%, which changed the moving average for the period of 200-days by -82.67% in comparison to the 20-day moving average, which settled at $0.4399. In addition, Virios Therapeutics Inc saw -35.20% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VIRI starting from Pridgen William, who purchase 15,335 shares at the price of $1.30 back on Aug 21 ’23. After this action, Pridgen William now owns 52,045 shares of Virios Therapeutics Inc, valued at $19,992 using the latest closing price.
Duncan Gregory Scott, the CHIEF EXECUTIVE OFFICER of Virios Therapeutics Inc, purchase 25,000 shares at $1.25 during a trade that took place back on Aug 17 ’23, which means that Duncan Gregory Scott is holding 57,461 shares at $31,245 based on the most recent closing price.
Stock Fundamentals for VIRI
The total capital return value is set at -1.43. Equity return is now at value -95.14, with -84.50 for asset returns.
Currently, EBITDA for the company is -5.45 million with net debt to EBITDA at 0.61. The liquidity ratio also appears to be rather interesting for investors as it stands at 11.62.
Conclusion
In summary, Virios Therapeutics Inc (VIRI) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
